Advertisement Pharmaceutical Business review - Page 684 of 5261 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
February 17, 2026

ExCellThera secures German NUB Status 1 listing for Zemcelpro

ExCellThera and its wholly owned subsidiary Cordex Biologics have received a Status 1 listing from the Neue Untersuchungs- und Behandlungsmethoden (NUB) programme in Germany for Zemcelpro (dorocubicel), also known as UM171 Cell Therapy.

Over 120 patients with haematologic malignancies took part in clinical trials across Canada, Europe, and the US. Credit: Anamaria Mejia / Shutterstock.com.